: AstraZeneca’s U.S. stock falls on report of coronavirus study halt

/ / News

U.S.-traded shares of AstraZeneca PLC AZN fell in the extended session Tuesday following a report that the drug maker halted a COVID-19 vaccine study following an adverse reaction from a participant. American depositary shares of AstraZeneca dropped 6% after hours, following a 2.1% rise to close at $54.71 in the regular session. The drug maker said the Phase 3 clinical study is on hold while it reviews an suspected adverse reaction in the U.K., according to a report by Stat late Tuesday. At the end of August, AstraZeneca had announced that the clinical trial had moved into a late-stage study that was seeking 30,000 participants.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.